For the treatment of grass allergies,
Start early
Keep going
For symptom relief

Give your patients the momentum to make it
through grass allergy season with ORALAIR—a
5-grass sublingual allergy immunotherapy tablet.1

Get Started Today
Efficacy

Efficacy during the first pollen season in children, adolescents, and adults and long-term grass allergy relief.1-3,4

Safety

Demonstrated safety profile in adults, children, and adolescents1

Dosing

Administered at home after the first in-office dose1

Why Oralair

Give your grass allergy patients momentum

Initiated before the grass allergy season to get patients ahead of grass allergy symptoms.

Treatment started 4 months prior to the start of grass allergy season and continued throughout the pollen season1
Daily at-home administration after patients tolerate the first in-office dose1— Patients observed for 30 minutes in-office to monitor for signs of severe systemic or severe local reaction

The only sublingual grass allergy immunotherapy tablet that contains 5 common grasses widely distributed throughout America1,2

Prevalence of the 5 grasses contained in ORALAIR (Sweet vernal, orchard, perennial rye, timothy, and Kentucky blue grasses) across the contiguous United States

For symptom relief during
the first pollen season

Significant improvement in efficacy measures during the pollen
period in adults1,3*

CS, Combined Score; RTSS, Rhinoconjunctivitis Total Symptom Score; RMS, Rescue Medicine Score; RSS, Rhinoconjunctivitis Symptom Score.

Significant improvement in efficacy measures during the pollen period in
children and adolescents1,4||

  • Rhinoconjunctivitis symptoms rated included sneezing, rhinorrhea, nasal pruritus, nasal congestion, ocular pruritus, and watery eyes1

The momentum for
long-term symptom relief

Sustained efficacy, year after year, for 3 years1,4
—Improvement in CS as measured during treatment

  • Data are insufficient to demonstrate efficacy for 1 or 2 years after discontinuation of ORALAIR.1

* A multicenter clinical trial of 473 adults in the United States.1

Combined Score is a patient-specific measure that combines symptom and medication scores. It is calculated as CS=[(RTSS/6)+RMS]/2, ranging from 0 to 3.1,4

Participants graded each symptom daily using a 4-point descriptor scale for each symptom (0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms). Daily RTSS was the sum of the 6 individual RSSs.1

§ Graded the intake of rescue medication as 0 = no medication; 1 = antihistamine (oral drops, eye drops, or both); 2 = nasal corticosteroid; 3 = oral corticosteroid.1

|| A multicenter clinical trial of 278 children and adolescents.1

A 5-year, multicenter clinical trial of 426 adults in European countries. Patients were treated with ORALAIR or placebo starting 4 months before the start of grass allergy season for 3 years, followed by 2 years of immunotherapy-free follow-up.1,5

Demonstrated safety profile in adults1#

Adverse reactions reported by ≥2% of adults 18 through 65 years of age receiving ORALAIR®
300 IR and at a greater incidence than placebo1

  • Additional adverse reactions of interest that occurred in >2% of ORALAIR recipients included
    dysphagia, nausea, vomiting, esophageal pain, gastritis, and gastroesophageal reflux1
  • ORALAIR should be used during pregnancy or breastfeeding only if clearly needed1
  • ORALAIR has not been studied in patients over 65 years of age1

IR, index of reactivity.
#Safety results from 6 placebo-controlled clinical trials of 1038 adults ages 18 through 65 receiving at least 1 dose of
ORALAIR 300 IR.1

Demonstrated safety profile in
children and adolescents1

Additional adverse reactions reported by ≥2% of children and adolescents
receiving ORALAIR 300 IR and at a greater incidence than placebo1

  • The safety profile in the pediatric population was generally similar to that of adults1
  • Efficacy and safety of ORALAIR have been established in children and adolescents 10 through 17 years of age. ORALAIR is not
    approved for use in children younger than 10 years of age because safety has not been established1
  • ORALAIR is indicated for pediatric patients over ten years of age1

Adverse reactions in a pivotal multicenter, multinational clinical trial of 278 children and adolescents6

  • Localized treatment-emergent adverse reactions occurred in 54% of subjects treated with ORALAIR6
  • Adverse reactions in ≥5% of patients included oral pruritus (32.4%), edema of the mouth (12.9%), and
    throat irritation (7.9%)6
  • Localized treatment-emergent adverse events were1:
    • Usually mild to moderate6
    • Transient, often resolving within the first week of treatment7
  • Only 7 ORALAIR-treated subjects discontinued due to adverse reactions6
  • 2 subjects who received ORALAIR reported serious adverse events, but they were not attributed to treatment6,8
    • These serious adverse events included asthma exacerbation and Burkitt lymphoma

  • Treatment-emergent adverse events were mild to moderate and often resolved within 1 week of treatment in adult and pediatric groups3,7

Started 4 months before grass
allergy season and maintained
until season’s end1

Dosage for adults and children1

  • Observe patients for 30 minutes for signs or symptoms of a severe systemic or severe local allergic
    reaction after providing the first dose in-office1
  • After tolerating the first in-office dose, patients can take subsequent doses at home1
  • If patients do not take ORALAIR for more than 1 day, instruct them to contact you before restarting1
  • Administer ORALAIR to children under adult supervision1
  • It is recommended that auto-injectable epinephrine be made available to patients prescribed ORALAIR.
    Patients who are prescribed epinephrine while receiving immunotherapy should be instructed in the proper
    use of emergency self-injection of epinephrine1
††ORALAIR 100 IR is not available commercially.

At-home administration after first
in-office dose

Administering ORALAIR®

Important considerations:

  • Administer ORALAIR to children under adult supervision
  • Auto-injectable epinephrine prescription is recommended1
    • Instruct patients on proper use of emergency self-injection of epinephrine

Get Started Today

Starter Packs available
to help you initiate
in-office treatment

A specialty pharmacy offers patients home
delivery or in-pharmacy pickup

  • After communicating your patient’s prescription to the specialty pharmacy, ORALAIR is
    delivered right to their door
  • If your patient prefers to pick up their ORALAIR prescription, an in-store pickup option
    is available at local participating retail pharmacies

HubExpress, a feature of CoverMyMeds

  • Offers prior authorization assistance and monitoring
  • Enhances the prior authorization workflow
  • Creates a more efficient workflow allowing for fewer phone calls to your providers
  • Keeps providers informed of prior authorization request status throughout the
    prior authorization lifecycle
  • Provides a platform to assist HCPs with the submission of appeals, if needed

Ongoing adherence support through All-Points Allergy™
patient support program

  • Timely grass allergy management information and ORALAIR treatment information provided
  • Monthly refill and seasonal re-activation reminders
  • Co-pay assistance available to eligible patients